🌟 Calling all members of the PANS/PANDAS community! 🌟
Research Update – Clinical Neuroimmunology Group, Children’s Hospital at Westmead and University of Sydney
The Clinical Neuroimmunology Group, led by Prof Russell Dale, at the Children’s Hospital at Westmead (Sydney) is preparing a research grant proposal focusing on developing new treatments for children with PANS. Please click the link below to find out more about this project and provide your feedback.
🔗 Click the link below to learn more about the project and share your valuable feedback: https://redcap.sydney.edu.au/surveys/?s=JRPMRKCHTXML9DM9
💊 “This project aims to provide evidence that azithromycin, ibuprofen, and butyrate lead to biological changes and clinical improvement of neuropsychiatric symptoms in children with PANS. The results from this study will lay the foundation for future randomised controlled trials investigating these drugs in larger cohorts of children with PANS. We hope this evidence will legitimise these treatments as viable and accessible options for children with PANS.”
Help shape the future of treatments for children with PANS by providing feedback. Together, let’s make a difference in the lives of children affected by PANS. Your input matters! 🧡 #PANSresearch #CommunityFeedback #ChildrensHealth #ResearchMatters
Gabriella True
2 comments to Research Update – Clinical Neuroimmunology Group, Children’s Hospital at Westmead and University of Sydney
David Kairys OD
November 3, 2024Please clue me in:
How come we have the cut-off at puberty?
Gabriella True
November 3, 2024Why does the PANDAS criteria have a prepubertal onset requirement? PANDAS is limited to a prepubertal onset to narrowly define the cohort; also, GAS is typically a pediatric illness, which allows for this narrowly defined cohort. PANS does not have an age requirement.